NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (NGAL): BIOMARKER URIN POTENSIAL DALAM DIAGNOSIS PENYAKIT GINJAL KRONIS

  • Ahmad Razi Maulana Alnaz Medical Faculty, University of Sumatera Utara
  • Rasyid Ridha Medical Faculty, University of Sumatera Utara
  • Aqyl Hanif Abdillah Medical Faculty, University of Sumatera Utara

Abstract

ABSTRAK


Pendahuluan: Penyakit Ginjal Kronis (PGK) adalah penyakit yang sering menjadi masalah kesehatan pada masyarakat, terutama pada lansia, sebagai akibat dari masalah kardiovaskular seperti obesitas dan hipertensi yang menjadi penyebab utama kematian lansia pada negara-negara berkembang. Tinjauan pustaka ini bertujuan untuk mengetahui kemampuan diagnostik dari NGAL urine dalam diagnosis PGK. Tinjauan pustaka ini dibuat dengan cara melakukan literature searching pada search engine seperti Google Scholar, PubMed, dan Sciencedirect, dengan menggunakan kata kunci NGAL, uNGAL, biomarker, CKD, dan elderly. Dari hasil pencarian, didapatkan sebanyak 37 jurnal sebagai bahan referensi.


Pembahasan: Dengan menganalisis literatur-literatur tersebut, didapatkan bahwa NGAL merupakan suatu polipeptida yang tergolong ke dalam kelompok lipocalin yang ekspresinya akan dijumpai meningkat pada keadaan inflamasi, termasuk pada ginjal. Dalam mendiagnosis PGK, kemampuan diagnostik NGAL urine yang dinyatakan dalam nilai AUC lebih tinggi dibandingkan dengan biomarker-biomarker lainnya. Selain itu, NGAL urine juga berkorelasi lebih kuat dengan penurunan faal ginjal dibandingkan dengan NGAL plasma.


Kesimpulan: Sebagai kesimpulan, NGAL urine merupakan suatu biomarker urin potensial dalam mendiagnosis PGK pada lansia.


Kata kunci: Biomarker, NGAL, PGK, Urin

Downloads

Download data is not yet available.

References

1. Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, et al. Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis. Remuzzi G, editor. PLoS One. 2016 Jul 6;11(7):e0158765.
2. Corbacıoglu SK, Cevik Y, Akinci E, Uzunosmanoglu H, Dagar S, Safak T, et al. Value of plasma neutrophil gelatinase-associated lipocalin (NGAL) in distinguishing between acute kidney injury (AKI) and chronic kidney disease (CKD). Turkish J Emerg Med. 2017;17(3):85–8.
3. CDC. CDC 2019 CKD fact sheet. Cdc [Internet]. 2019;1:1–6. Available from: https://www.cdc.gov/kidneydisease/pdf/2019_National-Chronic-Kidney-Disease-Fact-Sheet.pdf
4. Wang F, Yang C, Long J, Zhao X, Tang W, Zhang D, et al. Executive summary for the 2015 Annual Data Report of the China Kidney Disease Network (CK-NET). Kidney Int. 2019;95(3):501–5.
5. Pusat Data dan Informasi Kemenkes RI. Situasi Penyakit Ginjal Kronis [Internet]. Kementerian Kesehatan Republik Indonesia; 2017. Available from: https://pusdatin.kemkes.go.id/article/view/17050400001/situasi-penyakit-ginjal-kronis.html
6. Milik A, Hrynkiewicz E. On translation of LD, IL and SFC given according to IEC-61131 for hardware synthesis of reconfigurable logic controller. IFAC Proc Vol. 2014;19(1):4477–83.
7. Guo L, Zhu B, Yuan H, Zhao W. Evaluation of serum neutrophil gelatinase‐associated lipocalin in older patients with chronic kidney disease. Aging Med. 2020;3(1):35–42.
8. Rysz J, Gluba-Brzózka A, Franczyk B, Jablonowski Z, Cialkowska-Rysz A. Novel biomarkers in the diagnosis of chronic kidney disease and the prediction of its outcome. Int J Mol Sci. 2017;18(8).
9. Gharishvandi F, Kazerouni F, Ghanei E, Rahimipour A, Nasiri M. Comparative assessment of neutrophil gelatinase-associated lipocalin (NGAL) and cystatin c as early biomarkers for early detection of renal failure in patients with hypertension. Iran Biomed J. 2015;19(2):76–81.
10. Guo L, Zhao Y, Yong Z, Zhao W. Evaluation value of neutrophil gelatinase-associated lipocalin for the renal dysfunction of patients with chronic kidney disease: A meta-analysis. Aging Med. 2018;1(2):185–96.
11. Hassanzadeh R, Lasserson D, Price CP, Heneghan C, Van den Bruel A, Plüddemann A. Neutrophil gelatinase-associated lipocalin: primary care diagnostic technology update. Br J Gen Pract. 2016;66(651):542–3.
12. Virzì GM, Clementi A, De Cal M, Cruz DN, Ronco C. Genomics and biological activity of neutrophil gelatinase-associated lipocalin in several clinical settings. Blood Purif. 2013;35(1–3):139–43.
13. Chakraborty S, Kaur S, Guha S, Batra SK. The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer. Biochim Biophys Acta - Rev Cancer. 2012 Aug;1826(1):129–69.
14. Chakraborty S, Kaur S, Tong Z, K. S, Guh S. Neutrophil Gelatinase Associated Lipocalin: Structure, Function and Role in Human Pathogenesis. In: Veas F, editor. Acute Phase Proteins - Regulation and Functions of Acute Phase Proteins [Internet]. InTech; 2011. p. 345–68. Available from: https://www.intechopen.com/books/advanced-biometric-technologies/liveness-detection-in-biometrics
15. Candido S, Maestro R, Polesel J, Catania A, Maira F, Signorelli SS, et al. Roles of neutrophil gelatinase-associated lipocalin (NGAL) in human cancer. Oncotarget. 2014;5(6):1576–94.
16. Singer E, Markó L, Paragas N, Barasch J, Dragun D, Müller DN, et al. Neutrophil gelatinase-associated lipocalin: pathophysiology and clinical applications. Acta Physiol. 2013 Apr;207(4):663–72.
17. Forster CS, Devarajan P. Neutrophil gelatinase-associated lipocalin: utility in urologic conditions. Pediatr Nephrol [Internet]. 2017 Mar 26;32(3):377–81. Available from: http://link.springer.com/10.1007/s00467-016-3540-0
18. Chen B, Li Y, Liu Y, Zang C, Wu M, Xu Z. Diagnostic value of neutrophil gelatinase-associated lipocalin in diabetic nephropathy: a meta-analysis. Ren Fail. 2019;41(1):489–96.
19. Haase-Fielitz A, Haase M, Devarajan P. Neutrophil gelatinase-associated lipocalin as a biomarker of acute kidney injury: A critical evaluation of current status. Ann Clin Biochem. 2014;51(3):335–51.
20. Cho SY, Hur M. Neutrophil gelatinase-associated lipocalin as a promising novel biomarker for early detection of kidney injury. Ann Lab Med. 2018;38(5):393–4.
21. Yim HE. Neutrophil Gelatinase-Associated Lipocalin and Kidney Diseases. Child Kidney Dis. 2015;19(2):79–88.
22. Devarajan P. The Use of Targeted Biomarkers for Chronic Kidney Disease. Adv Chronic Kidney Dis. 2010 Nov;17(6):469–79.
23. Schrezenmeier E V., Barasch J, Budde K, Westhoff T, Schmidt-Ott KM. Biomarkers in acute kidney injury – pathophysiological basis and clinical performance. Acta Physiol. 2017;219(3):554–72.
24. Lee H-E, Lee SH, Baek M, Choi H, Park K. Urinary Measurement of Neutrophil Gelatinase Associated Lipocalin and Kidney Injury Molecule-1 Helps Diagnose Acute Pyelonephritis in a Preclinical Model. J Biomarkers. 2013;2013:1–6.
25. Krzeminska E, Wyczalkowska-Tomasik A, Korytowska N, Paczek L. Comparison of Two Methods for Determination of NGAL Levels in Urine: ELISA and CMIA. J Clin Lab Anal. 2016;30(6):956–60.
26. Nitta K, Okada K, Yanai M, Takahashi S. Aging and chronic kidney disease. Kidney Blood Press Res. 2014;38(1):109–20.
27. Stevens LA, Viswanathan G, Weiner DE. Chronic Kidney Disease and End-Stage Renal Disease in the Elderly Population: Current Prevalence, Future Projections, and Clinical Significance. Adv Chronic Kidney Dis. 2010;17(4):293–301.
28. Mallappallil M, Friedman EA, Delano BG, Mcfarlane SI, Salifu MO. Chronic kidney disease in the elderly: Evaluation and management. Clin Pract. 2014;11(5):525–35.
29. Ataei N, Ameli S, Yousefifard M, Oraei A, Ataei F, Bazargani B, et al. Urinary Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Cystatin C in Early Detection of Pediatric Acute Kidney Injury; a Diagnostic Accuracy Study. Emergency. 2018;6(1):e2–e2.
30. Gan J, Zhou X. Comparison of urine neutrophil gelatinase-associated lipocalin and interleukin-18 in prediction of acute kidney injury in adults. Med (United States). 2018;97(39).
31. Sola-Del Valle DA, Mohan S, Cheng JT, Paragas NA, Sise ME, D’Agati VD, et al. Urinary NGAL is a useful clinical biomarker of HIV-associated nephropathy. Nephrol Dial Transplant. 2011;26(7):2387–90.
32. Kaul A, Behera M, Rai M, Mishra P, Bhaduaria D, Yadav S, et al. Neutrophil gelatinase-associated lipocalin: As a predictor of early diabetic nephropathy in Type 2 diabetes mellitus. Indian J Nephrol. 2018;28(1):53.
33. Murase K, Mori K, Yoshimura C, Aihara K, Chihara Y, Azuma M, et al. Association between Plasma Neutrophil Gelatinase Associated Lipocalin Level and Obstructive Sleep Apnea or Nocturnal Intermittent Hypoxia. PLoS One. 2013;8(1):1–7.
34. Wang J, Lv H, Luo Z, Mou S, Liu J, Liu C, et al. Plasma YKL-40 and NGAL are useful in distinguishing ACO from asthma and COPD. Respir Res. 2018;19(1):1–10.
35. Patel ML, Sachan R, Misra R, Kamal R, Shyam R, Sachan P. Prognostic significance of urinary NGAL in chronic kidney disease. Int J Nephrol Renovasc Dis. 2015;8:139–44.
36. Coppolino G, Comi N, Bolignano D, Patella G, Comi A, Provenzano M, et al. Urinary Neutrophil Gelatinase-Associated Lipocalin (NGAL) Predicts Renal Function Decline in Patients With Glomerular Diseases. Front Cell Dev Biol. 2020;8(May):1–7.
37. Bolignano D, Lacquaniti A, Coppolino G, Campo S, Arena A, Buemi M. Neutrophil gelatinase-associated lipocalin reflects the severity of renal impairment in subjects affected by chronic kidney disease. Kidney Blood Press Res. 2008;31(4):255–8.
Published
2022-01-31
How to Cite
ALNAZ, Ahmad Razi Maulana; RIDHA, Rasyid; ABDILLAH, Aqyl Hanif. NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (NGAL): BIOMARKER URIN POTENSIAL DALAM DIAGNOSIS PENYAKIT GINJAL KRONIS. Essential: Essence of Scientific Medical Journal, [S.l.], v. 19, n. 2, p. 32-37, jan. 2022. ISSN 2655-6472. Available at: <https://ojs.unud.ac.id/index.php/essential/article/view/71288>. Date accessed: 29 june 2022. doi: https://doi.org/10.24843/ESTL.2021.v19.i02.p06.